Treatment Patterns and Associated Outcomes in Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients Who Fail Imatinib 400 mg Daily
Time Perspective: Retrospective and Prospective
Observational
Observational Model: Cohort, Time Perspective: Retrospective
Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily
At 3 months post treatment change
No
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
United States: Institutional Review Board
CA180-240
NCT01394666
May 2011
December 2012
Name | Location |
---|